NeuroSigma Announces FDA Clearance of its Second-Generation
LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s...
Stay updated with breaking news from Checkmate Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s...
LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products. The Monarch external Trigeminal Nerve Stimulation (eTNS) System is indicated for treatment of pediatric attention deficit hyperactivity disorder (ADHD) as a monotherapy for patients ages 7 through 12 years old who are not currently taking prescrip
SEOUL, Korea and PASADENA, Calif., March 12, 2023 (GLOBE NEWSWIRE) -- Checkmate Capital Group, LLC (“Checkmate”) is pleased to announce the opening of...
Checkmate Capital makes preferred equity investment in Austrianova parent company SGAustria for GMP facility expansion
Further Announces Engagement of Checkmate Capital Group as International Advisor...